Trevena, Inc.

OTCPK:TRVN Stock Report

Market Cap: US$1.4k

Trevena Past Earnings Performance

Past criteria checks 0/6

There is insufficient data on Trevena's performance over the last few years.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Seeking Alpha • Aug 10

Trevena Q2 2022 Earnings Preview

Trevena (NASDAQ:TRVN) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.10 (-11.1% Y/Y) and the consensus Revenue Estimate is $0.31M (+72.2% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 2 downward. Revenue estimates have seen 0 upward revisions and 3 downward.
Seeking Alpha • Jul 29

Trevena slides on $2M preferred stock offering

Trevena (NASDAQ:TRVN) shares dropped 5% on Friday pre-market after the biopharmaceutical company announced preferred stock offering. The offering consists of 1,800 shares of Series A convertible preferred stock, 200 shares of Series B convertible preferred stock and warrants to purchase up to 8M shares of common stock. Each share of preferred stock has a stated value of $1,000 per share and a conversion price of $0.25 per share.  They are convertible into an aggregate of 8M shares of common stock. The warrants will be exercisable at $0.263/share, beginning on the later of six months following the date of issuance and the effective date of a reverse stock split of the company’s common stock in an amount sufficient to permit the exercise in full of the warrants. They will expire five and one-half years following the date of issuance. Offering is expected to close on or about July 29, 2022. Total gross proceeds will be $2M; net proceeds will be used for general corporate purposes.
Analysis Article • Jul 08

Trevena (NASDAQ:TRVN) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 19

Is Trevena (NASDAQ:TRVN) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Dec 14

Trevena Offers An Enticing Risk-Reward At These Prices

Trevena continues to struggle to get OLINVYK off the launch pad. COVID-19 headwinds are persisting, and it is having an impact on the company's ability to get through P&T committees. Trevena is building a body of evidence in OLINVYK's post-approval program. The company expects these additional studies should improve product adoption and potentially expand OLINVYK's label. The market has crushed the share price under anemic volume. Now, TRVN's market cap is struggling to stay above $100M. I believe TRVN offers a great risk-reward at these prices. My "house money" position has gone from comfortably green, to a deep dark red. I am looking to change my strategy to claw my way back into green.
Seeking Alpha • Aug 17

Trevena: Remaining Patient After A Disappointing Q2 Earnings

Trevena recently reported disappointing Q2 earnings that revealed they completely missed the Street's expectations and only pulled in ~$180K in revenue. The COVID-19 headwinds are slamming Trevena and the forecast does not appear to be clearing up. As a result, I believe investors need to be patient with TRVN. Despite the underwhelming earnings, the company reported some encouraging commercial trends that could bode well for the second half of 2021 and potentially establish some momentum in 2022. I discuss why I am remaining patient with my TRVN and how I intend to manage this position as the world continues to deal with the ongoing pandemic.

Revenue & Expenses Breakdown

How Trevena makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:TRVN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241-341813
30 Jun 240-371916
31 Mar 243-402016
31 Dec 233-402016
30 Sep 233-312216
30 Jun 233-382517
31 Mar 230-453017
31 Dec 220-543518
30 Sep 220-613919
30 Jun 220-594217
31 Mar 220-584216
31 Dec 211-523813
30 Sep 211-503713
30 Jun 213-413014
31 Mar 213-332314
31 Dec 203-291913
30 Sep 203-241512
30 Jun 200-271414
31 Mar 200-251413
31 Dec 190-251313
30 Sep 190-261313
30 Jun 193-221411
31 Mar 196-271713
31 Dec 186-311916
30 Sep 186-382120
30 Jun 183-492259
31 Mar 180-602054
31 Dec 170-722049
30 Sep 170-931942
30 Jun 170-107180
31 Mar 172-106170
31 Dec 164-1031690
30 Sep 166-82160
30 Jun 168-63140
31 Mar 168-55140
31 Dec 156-51130
30 Sep 154-48110

Quality Earnings: Insufficient data to determine if TRVN has high quality earnings.

Growing Profit Margin: Insufficient data to determine if TRVN's profit margins have improved over the past year.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if TRVN's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare TRVN's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if TRVN's earnings growth over the past year exceeded the Biotechs industry average.

Return on Equity

High ROE: TRVN has a negative Return on Equity (0%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 07:10
End of Day Share Price 2026/06/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Trevena, Inc. is covered by 13 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ying HuangBarclays
Ritu BaralCanaccord Genuity
Brandon FolkesCantor Fitzgerald & Co.